Results
1 -
10 of
99Cincinelli Raffaella, Musso Loana, Merlini Lucio, Giannini Giuseppe, Vesci Loredana, Milazzo Ferdinando M., Carenini Nives, Perego Paola, Penco Sergio, Artali Roberto, Zunino Franco, Pisano Claudio, Dallavalle Sabrina.
7-Azaindole-1-carboxamides as a new class of PARP-1 inhibitors, Bioorganic & Medicinal Chemistry, 2014 Elliott Richard J. R., Jarvis Ashley, Rajasekaran Mohan B., Menon Malini, Bowers Leandra, Boffey Ray, Bayford Melanie, Firth-Clark Stuart, Key Rebekah, Aqil Rehan, Kirton Stewart B., Niculescu-Duvaz Dan, Fish Laura, Lopes Filipa, McLeary Robert, Trindade Ines, Vendrell Elisenda, Munkonge Felix, Porter Rod, Perrior Trevor, Springer Caroline, Oliver Antony W., Pearl Laurence H., Ashworth Alan, Lord Christopher J..
Design and discovery of 3-aryl-5-substituted-isoquinolin-1-ones as potent tankyrase inhibitors, MedChemComm, 2015 Antitumor and anticancer stem cell activity of a poly ADP-ribose polymerase inhibitor olaparib in breast cancer cells, Breast Cancer Non-invasive PET Imaging of PARP1 Expression in Glioblastoma Models, Molecular Imaging and Biology PARP Inhibitors, Current Breast Cancer Reports PARP, Cancer Therapeutic Targets Dubach et al.
Quantitating drug-target engagement in single cells in vitro and in vivo.
Nature Chemical Biology, doi: 10.1038/nchembio.2248, published online 5 December 2016, Nature Chemical Biology Clinical Trials of PARP Inhibitors with Chemotherapy, PARP Inhibitors for Cancer Therapy Preclinical Chemosensitization by PARP Inhibitors, PARP Inhibitors for Cancer Therapy Classification of PARP Inhibitors Based on PARP Trapping and Catalytic Inhibition, and Rationale for Combinations with Topoisomerase I Inhibitors and Alkylating Agents, PARP Inhibitors for Cancer Therapy